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Abstract 
Background 
Recent reports have highlighted that diabetic patients with kidney failure are at 
increased risk of technique failure and transfer to haemodialysis within 90 days 
of initiating peritoneal dialysis. We wished to determine whether there were 
differences between diabetic and non-diabetic patients within the first 3 
months of starting peritoneal dialysis (PD). 
Methods 
We reviewed results of corresponding bioimpedance and the 1st test of 
peritoneal membrane function in consecutive patients, 6-10 weeks after 
initiating PD electively. 
Results 
386 adult patients, 230 males (59.6%), 152 (39.4%) diabetic, 188 (48.7%) white 
ethnicity, mean age 57.3 ±16.9 years were studied. Although weight, residual 
renal function and peritoneal clearances were not different, diabetic patients 
had greater extracellular water to total body water (ECW/TBW) (40.4±1.1 vs 
39.2±1.4) and %ECW excess (9.6 (6.3-12.3) vs 4.9 (0.7-8.9)), lower serum 
albumin (35.2±4.7 vs 37.8±4.9 g/L), greater fat mass index (9.5±4.2 vs 7.7±4.2), 
and although mean arterial blood pressure was similar, arterial pulse pressure 
was greater 66.9±10.8 vs 54.3±17.3 mmHg, all p<0.001. On multivariate analysis, 
glycated haemoglobin was associated with pulse pressure (standardised β 0.24, 
p<0.001), N terminal brain natriuretic peptide (β 0.24, p<0.001), ECW/TBW (β 
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0.19, p=0.012), and negatively with serum albumin (β- 0.14, p=0.033) and 
creatinine (β- 0.18, p=0.02). 
Conclusion 
Diabetic patients electively starting PD were found to have greater ECW/TBW 
ratios and ECW excess 6-10 weeks after starting PD compared to non-diabetics, 
despite similar peritoneal membrane function. Increased ECW could predispose 
diabetic patients to be at greater risk of volume overload 
 
Introduction 
More than 300,000 patients with chronic kidney disease are now treated 
by peritoneal dialysis worldwide. Although some of this expansion in peritoneal 
dialysis has been due to a peritoneal dialysis first approach adopted by some 
countries in the Asia-Pacific region, there have been programmes to increase 
patient uptake in both North America and the UK.  However, the average 
duration of treatment with peritoneal dialysis remains much less than that for 
haemodialysis, with peritonitis [1] and ultrafiltration failure being the 
commonest causes of technique failure for patients established on peritoneal 
dialysis [2]. Although peritoneal dialysis may incur lower health care treatment 
costs, episodes of peritonitis and acute transfer to haemodialysis considerably 
increase health care expenditure [3]. A recent study from North America 
reported that almost 30% of patients initiating peritoneal dialysis changed 
modality to haemodialysis within the first 90 days [4].  
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Diabetic patients have been reported to be are at greater risk of 
modality transfer to haemodialysis [5]. It is unclear as to whether this is due to 
glucose control or additional co-morbidities associated with diabetes and chronic 
kidney disease. Diabetic patients established on peritoneal dialysis have been 
reported to have accelerated loss of residual renal function and weight gain, 
which could be associated with extracellular water expansion and ultrafiltration 
failure [6,7].  
However diabetic patients have also been reported to be at risk of early 
transfer to haemodialysis within the first 90 days of treatment [4]. As such we 
wished to review whether there were differences in peritoneal membrane 
function and volume assessments in diabetic patients attending for their first 
assessment of peritoneal membrane function 6-10 weeks after completing 
peritoneal dialysis training compared to non-diabetic patients. 
 
Patients and methods 
 We reviewed the results of consecutive adult patients attending for 
their first assessment of peritoneal membrane function between 6 and 10 weeks 
after completing peritoneal dialysis training [8], who had corresponding 
bioimpedance assessments.  Detailed methods are described in the supplemental 
methods section. Patients had started peritoneal dialysis electively, and none as 
an emergency, and no patient had suffered peritonitis since starting dialysis.  
Patient related data was obtained from hospital computerised records 
and co-morbidity assessed using the Stoke-Davies grading scales [9]. 
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 This retrospective audit of standard routine clinical practice fulfilled the 
UK NHS guideline for clinical audit and service development (UK NHS guidelines 
for clinical audit and service development, available at 
http://www.hra.nhs.uk/documents/2013/09/defining-research.pdf, and 
http://www.gov.uk/government/publications/health-research-ethics-
committees-governancearrangements). All patient data was appropriately 
anonymised. 
 
Statistical analysis 
 Statistical analysis was by t test, or Man Whitney U  analysis, Anova or 
Kruskal Wallis with appropriate post-hoc correction for  multiple analyses, and 
by Chi square test or Fisher’s exact test. Spearman analysis was used for 
univariate analysis, and ancova for extracellular water measurements prior to 
and after starting PD, and then non-parametric data was log transformed for 
multivariable step backward linear analysis, using all variables with a p<0.1 
correlation, with variables excluded if not statistically significant, unless they 
improved the model fit. Models were checked for variable inflation factor and 
collinearity (GraphPad Prism version 6.0, San Diego, USA, SPSS 24, University 
Chicago, USA). Data are presented as mean ± standard deviation, median (inter 
quartile range) or as a percentage. Statistical significance was taken at p<0.05. 
 
Results 
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 We reviewed the results of peritoneal membrane testing in 386 adult 
patients, 230 males (59.6%), 152 diabetic (39.4%), mean age 57.3 ±16.9 years, 
median timing of PET 8 weeks (6-10). Most patients were of white ethnicity, 188 
(48.7%), followed by African-Afro-Caribbean 91 (23.6%), South Asian 80 
(20.7%), and Far Asian 22 (5.7%). 78 (20.2%) patients were treated by 
continuous ambulatory peritoneal dialysis (CAPD), 87 (22.5%) by automated 
peritoneal dialysis cycler (APD) with no day time exchange, and 221 (57.3%) by 
APD with a day time exchange. 294 patients (76.8%) were treated with one 7.5% 
icodextrin exchange, 126 were prescribed one or more 22.7 g/L dextrose 
exchanges (32.9%), and no patient used greater glucose concentrations. Eighty 
one (21%) patients were prescribed neutral pH dialysates (Physioneal, Baxter 
Health Corporation, Deerfield, Illinois, USA). At 6 months, 331 (85.8%) patients 
remained on peritoneal dialysis, 24 (6.2%) had been transplanted, 26 (6.7%) 
transferred to haemodialysis (supplemental table) and 7 (1.8%) had died. 
 Diabetic patients were older, and there were more non-white diabetic 
patients from (X2=15.1p=0.005) (table 1). Although body weight was similar, 
diabetic subjects had greater body mass index (BMI). Mean arterial blood 
pressure was similar between diabetics and non-diabetics, but diabetic patients 
were prescribed more anti-hypertensive medications (X2=16.8, p=0.005), and 
had a higher pulse pressure (table 1). Diabetic patients had lower serum 
cholesterol and triglyceride concentrations and more were prescribed HMG 
CoA3 reductase inhibitors (statins). C reactive protein concentration and serum 
albumin lower. 98 (41.9%) non-diabetic patients had grade one co-morbidity and 
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14 (6%) grade 2, compared to 72.4% of diabetics with grade one co-morbidity 
and 27.6% grade 2 (X2=121.7, p<0.001). At 6 months 84.3 % of diabetics 
remained on peritoneal dialysis and 10.5% had transferred to haemodialysis, 
compared to 86.7% and 4.3% for the non-diabetics. 
 As peritoneal clearances, may be affected by body size, we analysed 
peritoneal membrane function separately for male and female patients (table 2). 
As expected, male patients had greater weight with greater muscle mass and 
less body fat. There were no differences in residual renal clearances or 
peritoneal or total clearance. Female diabetic patients were faster transporters 
than non-diabetics, but transporter status was similar between male diabetics 
and non-diabetics. Diabetic patients had greater body fat and increased 
ECW/TBW and excess ECW (Figure 1). NT-proBNP was higher in male diabetic 
patients and albumin lower in diabetics, with male diabetics having a lower 
estimated nPNA. Diabetic patients had greater co-morbidity, but there were no 
differences between the sexes. 
 Glycated haemoglobin results (reported in mmol/mol as per guidelines 
International Federation of Clinical Chemists (IFCC)) were available for 347 
(89.9%) patients, including all diabetic patients. On univariate analysis, glycated 
haemoglobin was associated with mean arterial pressure, pulse pressure, ECW 
excess, body fat and C reactive protein (CRP) and lower serum cholesterol, 
sodium, albumin, urea and creatinine, nPNA and sodium excretion. However, on 
restricting analysis to those with diabetes, statistical significance was lower or 
lost (pulse pressure r= 0.19, p=0.02, ECW/TBW ratio r =0.05, p=0.58). On multi-
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variable analysis (table 3), after excluding variables for collinearity, then pulse 
pressure, NT-proBNP and the ratio of ECW/TBW remained associated with  
glycated haemoglobin Whereas IFCC glycated haemoglobin was negatively 
associated with serum albumin and creatinine (table 4). 
 Bioimpedance measurements were available in a subset of 145 patients at 
the time of training prior to commencing peritoneal dialysis, and on ancova 
testing, comparing starting and then at the time of peritoneal membrane testing 
ECW/TBW and ECW excess were significantly greater for diabetic patients 
(f=12.7, f=13.1, respectively, p=0.001). The ratio of ECW/TBW was similar 
starting peritoneal dialysis, but increased for the diabetic cohort (starting 
39.2±1.6 vs 39.1±1.6 and at peritoneal membrane testing 39.4±1.4 vs 39.1±1.4). 
   
 Discussion 
 Previous reports have shown that whereas haemodialysis patients have a 
change in hydration status with dialysis sessions, peritoneal dialysis patients are 
generally volume expanded with an increased ECW/TBW ratio [10]. However, 
this ECW expansion does not necessarily reflect increased plasma volume, as 
ECW excess does not increase peritoneal ultrafiltration [7] or preserve residual 
renal function [11]. Some studies have suggested that this increase in ECW may 
be secondary to increased vascular permeability and albumin transfer into 
interstitial tissues [12]. As such ECW expansion, has been reported to be both 
associated with increased risk of peritoneal dialysis technique failure [2] and 
patient mortality [13]. 
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 Patients with faster peritoneal transport may be at risk of retaining 
sodium and fluid due to faster loss of the peritoneal osmotic glucose gradient. 
We found that female diabetic patients had faster PET transport for creatinine 
and total proteins, and greater glucose absorption but there were no 
differences between male patients. However, we found no differences in net 
sodium balance. Faster transporter status can also be secondary to greater 
intra-peritoneal capillary surface area, which increases with body size, and can 
also be affected by hyperglycaemia causing vasodilatation [14]. However, the 
effects of faster transport status can be reduced using icodextrin [15] and the 
use of APD cyclers with shorter dwell times. As such more recent studies have 
not shown an association between faster transporter status in diabetic 
peritoneal dialysis patients and survival [16]. Although other studies have 
reported an association between faster peritoneal protein transport, which also 
may be increased by local or systemic inflammation [17], and hyperglycaemia may 
induce inflammatory vascular changes [14]. Although systolic blood pressure, and 
mean arterial blood pressure were similar between diabetic and non-diabetic 
patients, our diabetic subjects were prescribed more anti-hypertensive agents 
and we did note that diabetic patients had increased arterial pulse pressure, 
suggesting stiffening of major arteries. Pulse wave velocity has been reported 
to be greater in PD patients with increased ECW expansion [18]. However, this 
was a relatively small study and underpowered to determine whether there were 
differences for diabetic patients. Diabetic patients are recognised to be at risk 
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of arterial calcification, and more recently sodium deposition in the vasculature 
[19,20,]. 
 We found that diabetic patients had lower serum cholesterol and 
triglyceride concentrations. This may have been due to the greater prescription 
of statins in the diabetic patients, and although diabetic patients used more 
22.7 g/L glucose dialysates they also had a high usage of icodextrin dialysates, 
with 26.5% also using nutrineal. The combination of icodextrin and nutrineal has 
been shown to lower both cholesterol and triglycerides in diabetic peritoneal 
dialysis patients [21]. In addition to lower serum cholesterol, diabetic patients 
had lower serum sodium, urea, creatinine and albumin concentrations. Previous 
reports in peritoneal dialysis patients have suggested that fluid retention could 
lead to a dilutional effect [22]. However, hyperglycaemia can interfere with the 
standard laboratory measurement of sodium [23], and once we corrected for the 
glucose effect, serum sodium concentrations were not different, suggesting 
that these differences were not simply due to dilution. The lower urea and 
creatinine concentrations taken along with the lower nPNA could result from 
suggest lower dietary protein intake and creatinine generation. Some studies 
have suggested that diabetic patients and those with greater co-morbidity have 
lower active energy expenditure [24]. Bioimpedance can be used to assess body 
composition [25], and we noted that diabetic patients had more body fat, and 
male diabetic patients had less muscle mass when adjusted to height.  Our 
diabetic patients were older, and body composition can change with age. To 
minimise age related changes, we determined ECW excess, by comparing 
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measured ECW with that predicted from ICW normative data Diabetic patients 
had greater ECW than predicted, and in the subgroup who had starting 
bioimpedance data, this increased significantly in the diabetic patients since 
starting PD. 
On univariate analysis, glycated haemoglobin was negatively associated 
with total sodium losses, such that patients with higher IFCC glycated 
haemoglobin had lower sodium losses, suggesting that they could be at risk of 
sodium retention. This would be in keeping with the associations between 
increasing glycated haemoglobin and increased ECW/TBW and NTproBNP, along 
with arterial pulse pressure. However, increasing co-morbidity and inflammation 
have also been observed to increase ECW/TBW and NTproBNP [15]. This 
interaction would support the association with lower serum albumin, creatinine 
and nPNA. However, when analyses were restricted to the diabetic patients 
alone, then there was no association between ECW excess and glycated 
haemoglobin, suggesting the association is for diabetics, rather than glucose 
control per se. There is controversy as to the effect of diabetic control on 
outcomes in peritoneal dialysis patients [26,27]. The different results reported 
by studies may be related to confounders including whether single time point 
measurements of glycated haemoglobin reflect long-term time averaged diabetic 
control, the duration of diabetes and also insulin resistance, so called “pre-
diabetes”, and additional factors which may specifically affect glycated 
haemoglobin concentrations in PD patients [28]. 
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Although many diabetic patients with chronic kidney disease are 
successfully treated by peritoneal dialysis [29], other reports have suggested 
that diabetic patients are more likely to suffer early technique failure and 
transfer to haemodialysis [4]. Comparing diabetic patients at their first 
assessment of peritoneal membrane function we found that diabetic patients 
had evidence of ECW excess compared to non-diabetics as the measured ECW 
was greater than the ECW expected for the ICW, suggesting that diabetic 
patients had greater ECW. This association between ECW expansion and 
diabetes may potentially increase the risk of technique failure, but this 
hypothesis would require formal testing in a prospective trial. 
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Figure 1. Extracellular water excess compared to that expected for intracellular 
water for male and female patients [14]. *p<0.05 vs non-diabetics. 
 
Table 1.  Combined urinary urea and creatinine clearance (residual renal 
function). Results expressed as integer, mean ±SD, or median (interquartile 
range) or percentage.* p<0.05, ** <0.01, *** <0.001 vs non-diabetic 
 
 
Table 2. Body composition determined by bioimpedance and residual renal and 
peritoneal clearances, and peritoneal membrane function (PET) for diabetic and 
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non-diabetic patients. Mean arterial pressure (MAP), fat and soft mass indexed 
to height (FMI and SMI). Intracellular water (ICW), extracellular water (ECW), 
4 hour dialysate and serum samples (D4, S)) and time zero dialysate (D0), 
ultrafiltration volume (UF). Combined urinary urea and creatinine clearance 
(residual renal function), and urea clearance (Kturea), litres of creatinine (Lcreat), 
sodium (Na), normalised protein nitrogen appearance rate (nPNA), C reactive 
protein (CRP), N terminal brain natriuretic peptide (NTproBNP). International 
Federation Clinical Chemists (IFCC) measurement of glycated haemoglobin 
(IFCC). Stoke Davies co-morbidity grade (co-morbidity). Results expressed as 
integer, mean ±SD, or median (interquartile range) or percentage.* p<0.05, ** 
<0.01, *** <0.001 vs non-diabetic 
 
 
Table 3: Spearman univariate associations with International Federation Clinical 
Chemists (IFCC) measurement of glycated haemoglobin (IFCC). Serum sodium 
not corrected for glucose. 
 
 
Table 4; Step backward multivariable analysis using International Federation 
Clinical Chemists (IFCC) measurement of glycated haemoglobin (IFCC) which was 
log transformed. Unstandardised β (β) and standard error (StE) and 
standardised β (stβ), 95% confidence limits (95% CL). NT pro-brain natriuretic 
protein (NTproBNP), serum creatinine (creatinine), extracellular to total body 
water ratio (ECW/TBW). Model r=0.49, r2 =0.25, adjusted r2 = 0.23 
 
